Crossmark

Analysis of remobilization efficiency of etoposide combined with cytarabine and pegfilgrastim, with or without plerixafor, for multiple myeloma recurrence following autologous hematopoietic stem cell transplantation

Crossref DOI link: https://doi.org/10.1007/s10238-025-01784-y

Published Online: 2025-07-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhou, Yanhan

Qian, Honglan

Zheng, Jifu

Lu, Ying

Ye, Peipei
Funding

Funding for this research was provided by:

Medical Science and Technology Project of Zhejiang Province (2024KY1601)

Ningbo Medical & Health Leading Academic Discipline Project (2022-S05)

Ningbo Clinical Research Center for Ophthalmology (2022L003)
License Information

Text and Data Mining valid from 2025-07-14

Version of Record valid from 2025-07-14
More Information

Article History

Received: 19 June 2025

Accepted: 19 June 2025

First Online: 14 July 2025

Declarations

:

: The authors declare no competing interests.

: Approval was obtained from the ethics committee of the Affiliated People's Hospital of Ningbo University. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.

: Informed consent was obtained from all individual participants included in the study.

Document is current

Any future updates will be listed below